Date: 2014-01-13
Type of information: Development agreement
Compound: fibrosis therapy program
Company: UCB (Belgium) MRC Technology (UK)
Therapeutic area:
Type agreement: development
licensing
Action mechanism:
Disease: fibrosis
Details: * On January 13 2014, UCB and UK’s MRC Technology have announced that they have entered an exclusive license agreement, with UCB obtaining rights in a novel fibrosis therapy program. The program stems from a collaboration between MRC Technology’s Centre for Therapeutics Discovery and leading academics at the University of Sheffield on development of a novel antibody-based therapy which targets a key step in the progression of fibrosis.Under the terms of the agreement, MRC Technology will receive an upfront payment, clinical development milestone payments and royalties on future products. Consistent with the organization’s not-for-profit collaborative model, revenue from this deal is shared back with the University of Sheffield and will be reinvested to support other collaborative programs within its drug discovery labs. The target and financial terms of the agreement have not been disclosed.
Financial terms: Financial terms of the agreement have not been disclosed.
Latest news:
